Cargando…
High PD-L1 Expression Correlates with an Immunosuppressive Tumour Immune Microenvironment and Worse Prognosis in ALK-Rearranged Non-Small Cell Lung Cancer
High tumour programmed cell death-ligand 1 (PD-L1) expression is associated with poor progression-free survival (PFS) after tyrosine kinase inhibitor (TKI) therapy in ALK-rearranged non-small cell lung cancer (NSCLC). However, the characteristics of the tumour microenvironment (TME) and their progno...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10296689/ https://www.ncbi.nlm.nih.gov/pubmed/37371571 http://dx.doi.org/10.3390/biom13060991 |
_version_ | 1785063709103620096 |
---|---|
author | Tian, Xia Li, Yalun Huang, Qin Zeng, Hao Wei, Qi Tian, Panwen |
author_facet | Tian, Xia Li, Yalun Huang, Qin Zeng, Hao Wei, Qi Tian, Panwen |
author_sort | Tian, Xia |
collection | PubMed |
description | High tumour programmed cell death-ligand 1 (PD-L1) expression is associated with poor progression-free survival (PFS) after tyrosine kinase inhibitor (TKI) therapy in ALK-rearranged non-small cell lung cancer (NSCLC). However, the characteristics of the tumour microenvironment (TME) and their prognostic values in ALK-rearranged NSCLC are unknown. Here, we collected tumour tissues from pretreated ALK-rearranged NSCLC patients, immunohistochemical staining was used to assess PD-L1 expression, and tumour-infiltrating immune cells were determined via multiplex immunofluorescence staining (mIF). Our data showed that the median values of PFS for the high PD-L1 group and low PD-L1 group who received ALK-TKI treatment were 4.4 and 16.4 months, respectively (p = 0.008). The median overall survival (OS) of the two groups was 24.0 months and not reached, respectively (p = 0.021). Via univariate and multivariate analyses, a high PD-L1 expression and a worse ECOG PS were determined to be independent prognostic factors of OS (HR = 3.35, 95% CI: 1.23–9.11, p = 0.018; HR = 6.42, 95% CI: 1.45–28.44, p = 0.014, respectively). In addition, the high PD-L1 group had increased Tregs and exhausted CD8+ T cells in both the tumour and stroma (all p < 0.05). High PD-L1 expression was an adverse predictive and prognostic biomarker for ALK-rearranged NSCLC. The characteristics of the TME in patients with high PD-L1 expression were shown to have an immunosuppressive status. |
format | Online Article Text |
id | pubmed-10296689 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-102966892023-06-28 High PD-L1 Expression Correlates with an Immunosuppressive Tumour Immune Microenvironment and Worse Prognosis in ALK-Rearranged Non-Small Cell Lung Cancer Tian, Xia Li, Yalun Huang, Qin Zeng, Hao Wei, Qi Tian, Panwen Biomolecules Article High tumour programmed cell death-ligand 1 (PD-L1) expression is associated with poor progression-free survival (PFS) after tyrosine kinase inhibitor (TKI) therapy in ALK-rearranged non-small cell lung cancer (NSCLC). However, the characteristics of the tumour microenvironment (TME) and their prognostic values in ALK-rearranged NSCLC are unknown. Here, we collected tumour tissues from pretreated ALK-rearranged NSCLC patients, immunohistochemical staining was used to assess PD-L1 expression, and tumour-infiltrating immune cells were determined via multiplex immunofluorescence staining (mIF). Our data showed that the median values of PFS for the high PD-L1 group and low PD-L1 group who received ALK-TKI treatment were 4.4 and 16.4 months, respectively (p = 0.008). The median overall survival (OS) of the two groups was 24.0 months and not reached, respectively (p = 0.021). Via univariate and multivariate analyses, a high PD-L1 expression and a worse ECOG PS were determined to be independent prognostic factors of OS (HR = 3.35, 95% CI: 1.23–9.11, p = 0.018; HR = 6.42, 95% CI: 1.45–28.44, p = 0.014, respectively). In addition, the high PD-L1 group had increased Tregs and exhausted CD8+ T cells in both the tumour and stroma (all p < 0.05). High PD-L1 expression was an adverse predictive and prognostic biomarker for ALK-rearranged NSCLC. The characteristics of the TME in patients with high PD-L1 expression were shown to have an immunosuppressive status. MDPI 2023-06-15 /pmc/articles/PMC10296689/ /pubmed/37371571 http://dx.doi.org/10.3390/biom13060991 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Tian, Xia Li, Yalun Huang, Qin Zeng, Hao Wei, Qi Tian, Panwen High PD-L1 Expression Correlates with an Immunosuppressive Tumour Immune Microenvironment and Worse Prognosis in ALK-Rearranged Non-Small Cell Lung Cancer |
title | High PD-L1 Expression Correlates with an Immunosuppressive Tumour Immune Microenvironment and Worse Prognosis in ALK-Rearranged Non-Small Cell Lung Cancer |
title_full | High PD-L1 Expression Correlates with an Immunosuppressive Tumour Immune Microenvironment and Worse Prognosis in ALK-Rearranged Non-Small Cell Lung Cancer |
title_fullStr | High PD-L1 Expression Correlates with an Immunosuppressive Tumour Immune Microenvironment and Worse Prognosis in ALK-Rearranged Non-Small Cell Lung Cancer |
title_full_unstemmed | High PD-L1 Expression Correlates with an Immunosuppressive Tumour Immune Microenvironment and Worse Prognosis in ALK-Rearranged Non-Small Cell Lung Cancer |
title_short | High PD-L1 Expression Correlates with an Immunosuppressive Tumour Immune Microenvironment and Worse Prognosis in ALK-Rearranged Non-Small Cell Lung Cancer |
title_sort | high pd-l1 expression correlates with an immunosuppressive tumour immune microenvironment and worse prognosis in alk-rearranged non-small cell lung cancer |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10296689/ https://www.ncbi.nlm.nih.gov/pubmed/37371571 http://dx.doi.org/10.3390/biom13060991 |
work_keys_str_mv | AT tianxia highpdl1expressioncorrelateswithanimmunosuppressivetumourimmunemicroenvironmentandworseprognosisinalkrearrangednonsmallcelllungcancer AT liyalun highpdl1expressioncorrelateswithanimmunosuppressivetumourimmunemicroenvironmentandworseprognosisinalkrearrangednonsmallcelllungcancer AT huangqin highpdl1expressioncorrelateswithanimmunosuppressivetumourimmunemicroenvironmentandworseprognosisinalkrearrangednonsmallcelllungcancer AT zenghao highpdl1expressioncorrelateswithanimmunosuppressivetumourimmunemicroenvironmentandworseprognosisinalkrearrangednonsmallcelllungcancer AT weiqi highpdl1expressioncorrelateswithanimmunosuppressivetumourimmunemicroenvironmentandworseprognosisinalkrearrangednonsmallcelllungcancer AT tianpanwen highpdl1expressioncorrelateswithanimmunosuppressivetumourimmunemicroenvironmentandworseprognosisinalkrearrangednonsmallcelllungcancer |